First Trust Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $270K | Sell |
10,642
-289,990
| -96% | -$6.85M | ﹤0.01% | 2541 |
|
|
2026
Q1 | $6.79M | Buy |
300,632
+111,743
| +59% | +$2.48M | ﹤0.01% | 1286 |
|
|
2025
Q4 | $4.89M | Buy |
188,889
+179,147
| +1,839% | +$4.26M | ﹤0.01% | 1417 |
|
|
2025
Q3 | $251K | Buy |
+9,742
| New | +$239K | ﹤0.01% | 2455 |
|
|
2025
Q2 | – | Sell |
-49,192
| Closed | -$1.22M | – | 2685 |
|
|
2025
Q1 | $1.22M | Buy |
+49,192
| New | +$1.18M | ﹤0.01% | 1982 |
|
|
2024
Q4 | – | Sell |
-108,408
| Closed | -$1.63M | – | 2623 |
|
|
2024
Q3 | $1.63M | Buy |
108,408
+29,853
| +38% | +$510K | ﹤0.01% | 1838 |
|
|
2024
Q2 | $2.25M | Buy |
78,555
+43,848
| +126% | +$1.25M | ﹤0.01% | 1653 |
|
|
2024
Q1 | $1.01M | Sell |
34,707
-11,538
| -25% | -$354K | ﹤0.01% | 1980 |
|
|
2023
Q4 | $1.56M | Buy |
+46,245
| New | +$1.35M | ﹤0.01% | 1825 |
|
|
2023
Q3 | – | Sell |
-13,530
| Closed | -$542K | – | 2457 |
|
|
2023
Q2 | $542K | Buy |
+13,530
| New | +$559K | ﹤0.01% | 2119 |
|
|
2023
Q1 | – | Sell |
-36,491
| Closed | -$1.41M | – | 2444 |
|
|
2022
Q4 | $1.41M | Sell |
36,491
-19,414
| -35% | -$945K | ﹤0.01% | 1844 |
|
|
2022
Q3 | $2.97M | Sell |
55,905
-15,432
| -22% | -$858K | ﹤0.01% | 1460 |
|
|
2022
Q2 | $4.16M | Buy |
71,337
+36,469
| +105% | +$2.39M | 0.01% | 1337 |
|
|
2022
Q1 | $2.66M | Buy |
34,868
+20,791
| +148% | +$1.39M | ﹤0.01% | 1657 |
|
|
2021
Q4 | $847K | Buy |
14,077
+8,551
| +155% | +$471K | ﹤0.01% | 2122 |
|
|
2021
Q3 | $310K | Sell |
5,526
-23,010
| -81% | -$1.33M | ﹤0.01% | 2380 |
|
|
2021
Q2 | $1.73M | Buy |
28,536
+9,006
| +46% | +$570K | ﹤0.01% | 1862 |
|
|
2021
Q1 | $1.37M | Sell |
19,530
-24,613
| -56% | -$1.76M | ﹤0.01% | 1872 |
|
|
2020
Q4 | $2.64M | Sell |
44,143
-5,994
| -12% | -$351K | ﹤0.01% | 1437 |
|
|
2020
Q3 | $3.01M | Buy |
50,137
+3,177
| +7% | +$185K | ﹤0.01% | 1162 |
|
|
2020
Q2 | $2.46M | Buy |
46,960
+13,550
| +41% | +$566K | ﹤0.01% | 1284 |
|
|
2020
Q1 | $1.12M | Buy |
33,410
+4,013
| +14% | +$167K | ﹤0.01% | 1571 |
|
|
2019
Q4 | $1.33M | Sell |
29,397
-33,769
| -53% | -$1.43M | ﹤0.01% | 1761 |
|
|
2019
Q3 | $2.4M | Buy |
63,166
+49,780
| +372% | +$1.99M | ﹤0.01% | 1432 |
|
|
2019
Q2 | $582K | Sell |
13,386
-55,501
| -81% | -$2.36M | ﹤0.01% | 2053 |
|
|
2019
Q1 | $2.62M | Sell |
68,887
-11,757
| -15% | -$459K | 0.01% | 1403 |
|
|
2018
Q4 | $3.47M | Buy |
+80,644
| New | +$3.76M | 0.01% | 1169 |
|
|
2018
Q2 | – | Sell |
-18,733
| Closed | -$584K | – | 2460 |
|
|
2018
Q1 | $584K | Buy |
+18,733
| New | +$667K | ﹤0.01% | 1985 |
|
|
2015
Q1 | – | Sell |
-19,179
| Closed | -$1.7M | – | 2284 |
|
|
2014
Q4 | $1.7M | Sell |
19,179
-149
| -0.8% | -$14.1K | 0.01% | 1536 |
|
|
2014
Q3 | $1.87M | Buy |
19,328
+1,768
| +10% | +$172K | 0.01% | 1424 |
|
|
2014
Q2 | $1.61M | Buy |
+17,560
| New | +$1.34M | 0.01% | 1473 |
|
Other funds holding PCRX
DPCM
First Trust Advisors's PCRX Position: Q2 2026 in Review
First Trust Advisors reduced its Pacira BioSciences (PCRX) stake by 96% in Q2 2026, selling an estimated $6.85M and leaving 10,642 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #2541.
First Trust Advisors first reported a position in PCRX in Q2 2014 and has held it in 31 quarters since. The position peaked at $6.79M in Q1 2026. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- First Trust Advisors held 10,642 shares of Pacira BioSciences worth $270K as of Q2 2026.
- First Trust Advisors sold 289,990 Pacira BioSciences shares in Q2 2026, an estimated $6.85M.
- Pacira BioSciences made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2541 holding.
- First Trust Advisors first reported a position in Pacira BioSciences in Q2 2014 and has held it in 31 quarters since.
- First Trust Advisors's Pacira BioSciences position peaked at $6.79M in Q1 2026.
- 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.